Cargando…

Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy

INTRODUCTION: Sunitinib, a first-line therapy with a certain effect, was utilized in the early stages of renal cell carcinoma treatment. However, its clinical toxicity, side effects, and its limited bioavailability, resulted in inadequate clinical therapeutic efficacy. Building neoteric, simple, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xianhu, Teng, Yi, Zhu, Chunrong, Li, Zhipeng, Liu, Tian, Sun, Yong, Han, Shangcong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740013/
https://www.ncbi.nlm.nih.gov/pubmed/36510619
http://dx.doi.org/10.2147/IJN.S388234
_version_ 1784847952696573952
author Zeng, Xianhu
Teng, Yi
Zhu, Chunrong
Li, Zhipeng
Liu, Tian
Sun, Yong
Han, Shangcong
author_facet Zeng, Xianhu
Teng, Yi
Zhu, Chunrong
Li, Zhipeng
Liu, Tian
Sun, Yong
Han, Shangcong
author_sort Zeng, Xianhu
collection PubMed
description INTRODUCTION: Sunitinib, a first-line therapy with a certain effect, was utilized in the early stages of renal cell carcinoma treatment. However, its clinical toxicity, side effects, and its limited bioavailability, resulted in inadequate clinical therapeutic efficacy. Building neoteric, simple, and safe drug delivery systems with existing drugs offers new options. Therefore, we aimed to construct a micelle to improve the clinical efficacy of sunitinib by reusing ibuprofen. METHODS: We synthesized the sialic acid-poly (ethylene glycol)-ibuprofen (SA-PEG-IBU) amphipathic conjugate in two-step reaction. The SA-PEG-IBU amphiphilic conjugates can form into stable SPI nanomicelles in aqueous solution, which can be further loaded sunitinib (SU) to obtain the SPI/SU system. Following nanomicelle creation, sialic acid exposed to the nanomicelle surface can recognize the overexpressed E-selectin receptor on the membrane of cancer cells to enhance cellular uptake. The properties of morphology, stability, and drug release about the SPI/SU nanomicelles were investigated. Confocal microscopy and flow cytometry were used to assess the cellular uptake efficiency of nanomicelles in vitro. Finally, a xenograft tumor model in nude mice was constructed to investigate the body distribution and tumor suppression of SPI/SU in vivo. RESULTS: The result showed that SPI nanomicelles exhibited excellent tumor targeting performance and inhibited the migration and invasion of tumor cell in vitro. The SPI nanomicelles can improve the accumulation of drugs in the tumor site that showed effective tumor inhibition in vivo. In addition, H&E staining and immunohistochemical analysis demonstrated that the SPI/SU nanomicelles had a superior therapeutic effect and lower biotoxicity. CONCLUSION: The SPI/SU nanomicelles displayed excellent anti-tumor ability, and can suppress the metastasis of tumor cell by decreasing the expression of Cyclooxygenase-2 due to the ibuprofen, providing an optimistic clinical application potential by developing a simple but safe drug delivery system.
format Online
Article
Text
id pubmed-9740013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97400132022-12-11 Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy Zeng, Xianhu Teng, Yi Zhu, Chunrong Li, Zhipeng Liu, Tian Sun, Yong Han, Shangcong Int J Nanomedicine Original Research INTRODUCTION: Sunitinib, a first-line therapy with a certain effect, was utilized in the early stages of renal cell carcinoma treatment. However, its clinical toxicity, side effects, and its limited bioavailability, resulted in inadequate clinical therapeutic efficacy. Building neoteric, simple, and safe drug delivery systems with existing drugs offers new options. Therefore, we aimed to construct a micelle to improve the clinical efficacy of sunitinib by reusing ibuprofen. METHODS: We synthesized the sialic acid-poly (ethylene glycol)-ibuprofen (SA-PEG-IBU) amphipathic conjugate in two-step reaction. The SA-PEG-IBU amphiphilic conjugates can form into stable SPI nanomicelles in aqueous solution, which can be further loaded sunitinib (SU) to obtain the SPI/SU system. Following nanomicelle creation, sialic acid exposed to the nanomicelle surface can recognize the overexpressed E-selectin receptor on the membrane of cancer cells to enhance cellular uptake. The properties of morphology, stability, and drug release about the SPI/SU nanomicelles were investigated. Confocal microscopy and flow cytometry were used to assess the cellular uptake efficiency of nanomicelles in vitro. Finally, a xenograft tumor model in nude mice was constructed to investigate the body distribution and tumor suppression of SPI/SU in vivo. RESULTS: The result showed that SPI nanomicelles exhibited excellent tumor targeting performance and inhibited the migration and invasion of tumor cell in vitro. The SPI nanomicelles can improve the accumulation of drugs in the tumor site that showed effective tumor inhibition in vivo. In addition, H&E staining and immunohistochemical analysis demonstrated that the SPI/SU nanomicelles had a superior therapeutic effect and lower biotoxicity. CONCLUSION: The SPI/SU nanomicelles displayed excellent anti-tumor ability, and can suppress the metastasis of tumor cell by decreasing the expression of Cyclooxygenase-2 due to the ibuprofen, providing an optimistic clinical application potential by developing a simple but safe drug delivery system. Dove 2022-12-06 /pmc/articles/PMC9740013/ /pubmed/36510619 http://dx.doi.org/10.2147/IJN.S388234 Text en © 2022 Zeng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zeng, Xianhu
Teng, Yi
Zhu, Chunrong
Li, Zhipeng
Liu, Tian
Sun, Yong
Han, Shangcong
Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
title Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
title_full Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
title_fullStr Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
title_full_unstemmed Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
title_short Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
title_sort combined ibuprofen-nanoconjugate micelles with e-selectin for effective sunitinib anticancer therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740013/
https://www.ncbi.nlm.nih.gov/pubmed/36510619
http://dx.doi.org/10.2147/IJN.S388234
work_keys_str_mv AT zengxianhu combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy
AT tengyi combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy
AT zhuchunrong combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy
AT lizhipeng combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy
AT liutian combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy
AT sunyong combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy
AT hanshangcong combinedibuprofennanoconjugatemicelleswitheselectinforeffectivesunitinibanticancertherapy